Highlights: Phase I trial agreement with leading clinical research organization Human safety and tolerability study to assess infusion of RECCE® 327 in 40 healthy subjects as a single ascending...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.01 | -2.0618556701 | 0.485 | 0.485 | 0.47 | 25305 | 0.47479079 | DE |
4 | -0.025 | -5 | 0.5 | 0.5 | 0.435 | 60922 | 0.47178662 | DE |
12 | -0.08 | -14.4144144144 | 0.555 | 0.57 | 0.38 | 166015 | 0.47867598 | DE |
26 | 0.005 | 1.06382978723 | 0.47 | 0.57 | 0.38 | 163499 | 0.4848226 | DE |
52 | -0.05 | -9.52380952381 | 0.525 | 0.695 | 0.38 | 156551 | 0.49344073 | DE |
156 | -0.615 | -56.4220183486 | 1.09 | 1.38 | 0.38 | 143261 | 0.61637126 | DE |
260 | 0.1 | 26.6666666667 | 0.375 | 1.875 | 0.21 | 241482 | 0.79775758 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.